Bio-Techne Launches the Enhanced Leo™ System Delivering Advanced Multiplexing and High-Throughput Protein Analysis

Bio-Techne (NASDAQ: TECH) launched and shipped its enhanced Leo System on Dec 9, 2025, an upgraded Simple Western platform combining chemiluminescence with dual-channel near-infrared and infrared fluorescence for expanded multiplexing.

Rhea-AI Summary

Bio-Techne (NASDAQ: TECH) launched and shipped its enhanced Leo System on Dec 9, 2025, an upgraded Simple Western platform combining chemiluminescence with dual-channel near-infrared and infrared fluorescence for expanded multiplexing.

Key capabilities include up to 24 targets per sample, support for multiplexing same-weight targets and proteoform pairs (e.g., phosphorylated vs total), resampling and RePlex workflows, processing up to 100 capillaries in three hours, and reported precision of 5–6% variability. The system also includes features to support 21 CFR Part 11 compliance.

Positive

• Dual-channel NIR/IR fluorescence plus chemiluminescence expands multiplexing
• Enables up to 24 targets per sample
• Processes up to 100 capillaries in three hours
• Reported precision of 5–6% variability
• Includes features supporting 21 CFR Part 11 compliance

Negative

• None.

Argus Dec 9 session

-2.44% close to close Open Argus

Details

News Market Reaction – TECH

On Dec 9, the day this news came out, TECH closed 2.44% below the previous close.

Data tracked by StockTitan Argus for the Dec 9 session.

Key Figures

Multiplexing capacity: up to 24 targets per sample Capillary throughput: up to 100 capillaries in three hours Assay variability: 5–6% variability +5 more

Multiplexing capacity

up to 24 targets per sample

Enhanced Leo System protein analysis throughput

Capillary throughput

up to 100 capillaries in three hours

High-throughput Simple Western-based workflow

Assay variability

5–6% variability

Precision achieved in clinical research setting using Leo

21 CFR Part 11

Part 11 compliance support

Leo System supports 21 CFR Part 11 compliance needs

Price vs 52-week high

-23.95%

TECH price relative to 52-week high before launch news

52-week low

$46.01

Lower bound of TECH’s 52-week trading range pre-announcement

Market cap

$9,610,527,398

Equity value prior to Enhanced Leo System launch news

Short interest

3.29% of float

Reported short position in shares before this news

Historical Context

5 past events · Latest: Nov 25

5 events

1. Nov 25

   Investor conferences

   24h Move

   +3.7%

   Announcement of three early December investor conference presentations and webcasts.

2. Nov 18

   AI licensing deal

   24h Move

   -0.8%

   Exclusive license to NovoBody Duo AI-designed bispecific binding proteins from Monod Bio.

3. Nov 06

   Investor conferences

   24h Move

   -2.9%

   Schedule of four November healthcare investor conference appearances with webcasts.

4. Nov 05

   Earnings release

   24h Move

   -1.9%

   Q1 FY2026 results with slightly lower sales but higher margins and Exosome divestiture.

5. Nov 04

   AI clinical data

   24h Move

   -0.3%

   AI-powered spatial biology data in melanoma showing biomarker links to survival outcomes.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

chemiluminescence, near-infrared, infrared, proteomic, +4 more

8 terms

chemiluminescence medical

"Combines chemiluminescence detection with dual-channel fluorescence in the near-infrared..."

Chemiluminescence is light produced directly by a chemical reaction, similar to how a glow stick glows when its chemicals mix. In laboratory and medical testing it is used to make tiny amounts of a substance visible, so tests can detect disease markers or contaminants quickly and with high sensitivity. Investors care because chemiluminescent technologies power many diagnostic devices and assays, affecting product performance, regulatory approvals and potential revenue.

near-infrared medical

"dual-channel fluorescence in the near-infrared and infrared (NIR and IR) ranges..."

Near-infrared is the band of light just beyond what the human eye can see, similar to a flashlight beam shifted slightly into a color you can’t perceive. It penetrates materials and tissue differently than visible light, so it’s widely used in medical imaging, sensors, remote sensing and quality-control tools; for investors, that means technologies using near-infrared can enable new products, regulatory pathways and revenue streams tied to diagnostics, monitoring and industrial inspection.

infrared medical

"dual-channel fluorescence in the near-infrared and infrared (NIR and IR) ranges..."

Infrared is a band of light with wavelengths longer than visible red light that we cannot see but can feel as heat, like the warmth from the sun or a stovetop. Investors care because infrared technology — used in thermal cameras, night-vision, remote sensors, and some communication systems — drives demand for specific chips, sensors and manufacturing capacity, affecting revenue, margins and regulatory approvals in companies that build or use those products.

proteomic medical

"Strengthens Bio-Techne's leadership in proteomic analytical instruments..."

Proteomic describes something related to the large-scale study of proteins—the working parts inside cells that carry out functions and signal changes. For investors, proteomic work can reveal new drug targets, diagnostic tests or biomarkers that change a company’s potential revenue and risk profile; think of it like analyzing all ingredients in a recipe to find which ones can be improved or swapped to make a better product.

proteoforms medical

"assess different proteoforms, such as phosphorylated and total protein forms..."

Proteoforms are the different molecular versions of a single protein that arise from small changes in its blueprint, how the blueprint is read, or chemical tweaks added after the protein is made. For investors, proteoforms matter because they can change how a drug, diagnostic test, or biologic performs and how reliably a biomarker signals disease—think of one basic cookie recipe producing many different cookies depending on mix-ins and decorations.

phosphorylated medical

"assess different proteoforms, such as phosphorylated and total protein forms..."

Phosphorylated describes a molecule—most often a protein—that has had a small phosphate group chemically attached, like adding a tiny switch or Post‑it note that changes how the molecule behaves or where it goes. Investors care because phosphorylation is a common way cells turn processes on or off, so drugs, diagnostics, and safety signals often target or measure phosphorylated forms to show whether a treatment is working or causing unwanted effects.

21 CFR Part 11 regulatory

"supports 21 CFR Part 11 compliance"

21 CFR Part 11 is a U.S. regulatory rule that sets requirements for how electronic records and electronic signatures must be created, stored and protected so they can be trusted as if they were paper documents. For investors, it matters because companies that handle regulated data—like clinical trial results or manufacturing logs—must meet these controls or face regulatory delays, fines or lost market access; think of it as a lock-and-audit trail for digital paperwork.

absolute quantitation technical

"Leo represents the future of clinical research requiring absolute quantitation."

Absolute quantitation is a laboratory method that measures the exact amount of a molecule, virus, drug or biomarker in a sample and reports it in standard units (for example, copies per milliliter or micrograms per liter). Like counting exact bills in a cash register rather than estimating the till, it delivers precise, repeatable numbers that regulators, clinicians and investors use to validate tests, confirm dosing, assess disease burden and reduce uncertainty about product performance and market potential.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Combines chemiluminescence detection with dual-channel fluorescence in the near-infrared and infrared (NIR and IR) ranges for expanded multiplexing
  
  
• Enables up to 24 targets per sample and supports complex assay configurations
  
  
• Strengthens Bio-Techne's leadership in proteomic analytical instruments and supports 21 CFR Part 11 compliance

MINNEAPOLIS, Dec. 9, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced the expanded launch and first shipment of its next-generation Leo™ System, powered by Simple Western™ Technology.

The enhanced Leo System introduces dual-channel fluorescence detection alongside chemiluminescence, expanding data throughput and efficiency, and generating greater insights from precious samples. Fluorescence adds a fourth multiplexing option to its molecular weight separation, RePlex, and resampling capabilities to create even more experimental flexibility and tackle complex biological questions. This advance enables researchers to simultaneously quantify targets with distinct expression levels, assess different proteoforms, such as phosphorylated and total protein forms, in the same capillary, multiplex same-weight targets in a single run, and process up to 100 capillaries within three hours.

"Leo represents the future of clinical research requiring absolute quantitation. We chose Leo for its high-throughput capabilities and are consistently achieving highly precise results with only 5–6% variability, which is truly remarkable," said Alexandre Lucas, Ph.D., Founder and Manager of We-Met, a research group at the French National Institute of Health and Medical Research (INSERM).

"The next-generation Leo System sets a new standard for our customers by delivering unmatched precision and efficiency in protein analysis," said Will Geist, President of the Protein Sciences Segment at Bio-Techne. "With advanced detection technologies and built-in compliance features, Leo enables researchers to achieve faster, more reliable results, accelerate critical discoveries, and streamline development timelines."

Explore Leo's enhanced functionality at bio-techne.com/leo and view its new fluorescence-based detection capabilities.

ABOUT BIO-TECHNE:

Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated over $1.2 billion in net sales in fiscal 2025 and has approximately 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the company on social media at LinkedIn, X, or YouTube.

MEDIA CONTACTS:

Corporate Communications
media.relations@bio-techne.com

David Clair, Vice President
Investor Relations & Corporate Development
investor.relations@bio-techne.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-launches-the-enhanced-leo-system-delivering-advanced-multiplexing-and-high-throughput-protein-analysis-302635690.html

SOURCE Bio-Techne Corporation

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Bio-Techne announce about the Leo System on December 9, 2025 (TECH)?

Bio-Techne announced the enhanced Leo System with dual-channel NIR/IR fluorescence plus chemiluminescence and first shipments on Dec 9, 2025.

How many targets per sample can the Leo System (TECH) quantify with the new update?

The enhanced Leo System supports multiplexing of up to 24 targets per sample.

What throughput does the Leo System (TECH) achieve after the upgrade?

The system can process up to 100 capillaries within three hours.

What precision did users report for Leo System (TECH) results?

A user reported achieving highly precise results with 5–6% variability.

Does the Leo System (TECH) support regulatory compliance for clinical research?

The Leo System includes built-in features to help support 21 CFR Part 11 compliance.